Lack of Cetuximab induced skin toxicity in a previously irradiated field: Case report and review of the literature

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Kanakamedala, Madhava R ^a   Packianathan, Satyaseelan ^a   Vijayakumar, Srinivasan ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SUSCEPTIBILITY; CASE REPORT; CERVICAL LYMPH NODE; DRUG TARGETING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; IRRADIATION; LYMPH NODE METASTASIS; MALE; NECK; RASH; SKIN CANCER; SKIN GRAFT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; SKIN TUMOR;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; EXANTHEMA; HUMANS; MALE; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77952116631     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-38     Document Type: Article

References (19)

1. Garrett TPJ, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110(6):763-773. 10.1016/S0092-8674(02)00940-6, 12297049.
2. Ward CW, Lawrence MC, Streltsov VA, et al. The insulin and EGF receptor structures: new insights into ligand-induced receptor activation. Trends Biochem Sci 2007, 32(3):129-137. 10.1016/j.tibs.2007.01.001, 17280834.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139. 10.1056/NEJMoa040938, 15118073.
4. Nicholson RI, Gee JMW, Harper ME. EGFR and cancerprognosis. European Journal of Cancer 2001, 37(Supplement 4):9-15. 10.1016/S0959-8049(01)00231-3, 11165124.
5. Harari PM, Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin Radiat Oncol 2006, 16(1):38-44. 10.1016/j.semradonc.2005.08.005, 16378905.
6. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2006, 354(6):567-578. 10.1056/NEJMoa053422, 16467544.
7. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining?. J Clin Oncol 2005, 23(22):5235-5246. 10.1200/JCO.2005.00.6916, 16051966.
8. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001, 144(6):1169-1176. 10.1046/j.1365-2133.2001.04226.x, 11422037.
9. Lacouture ME, Lai SE. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006, 155(4):852-854. 10.1111/j.1365-2133.2006.07452.x, 16965448.
10. Nanney LB, Stoscheck CM, King LE, Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990, 94(6):742-748. 10.1111/1523-1747.ep12874601, 1693937.
11. Miettinen PJ, Berger JE, Meneses J, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376(6538):337-341. 10.1038/376337a0, 7630400.
12. Hopewell JW. The skin: its structure and response toionizing radiation. Int J Radiat Biol 1990, 57(4):751-773. 10.1080/09553009014550911, 1969905.
13. Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?. Int J Radiat Oncol Biol Phys 2000, 47(2):277-290. 10.1016/S0360-3016(00)00435-1, 10802350.
14. Bossi P, Liberatoscioli C, Bergamini C, et al. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 2007, 18(3):601-602. 10.1093/annonc/mdl409, 17074970.
15. Mitra SS, Simcock R. Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy Field. J Clin Oncol 2006, 24(16):e28-29. 10.1200/JCO.2005.05.1631, 16735697.
16. Acharya J, Lyon C, Bottomley DM. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin. J Am Acad Dermatol 2009, 60(1):154. 10.1016/j.jaad.2008.07.057, 19103369.
17. Yalçin S, Dizdar O, Yalçin B, Gököz O. Sparing of previously irradiated skin from erlotinib-induced acneiform rash. J Am Acad Dermatol 2008, 58(1):178-179. 10.1016/j.jaad.2006.10.988, 18158935.
18. Lacouture ME, Hwang C, Marymont MH, Patel J. Temporal Dependence of the Effect of Radiation on Erlotinib-Induced Skin Rash. J Clin Oncol 2007, 25(15):2140. 10.1200/JCO.2006.09.4045, 17513824.
19. Gerber PA, Enderlein E, Homey B, et al. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 2007, 25(29):4697-4698. 10.1200/JCO.2007.12.8330, 17925571.